Organic & Biomolecular Chemistry

Accepted Manuscript

This article can be cited before page numbers have been issued, to do this please use: J. Guo, Y. Hao, G. Li, Z. Wang, Y. Liu, Y. Li and Q. Wang, *Org. Biomol. Chem.*, 2020, DOI: 10.1039/D0OB00233J.



This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about Accepted Manuscripts in the Information for Authors.

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard <u>Terms & Conditions</u> and the <u>Ethical guidelines</u> still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.







ARTICLE

Received 00th January 20xx.

Accepted 00th January 20xx DOI: 10.1039/x0xx00000x

Efficient Synthesis of SCF₃-Substituted Tryptanthrins by a Radical Tandem Cyclization

Jincheng Guo,^{#a} Yanan Hao,^{#a} Gang Li,^a Ziwen Wang,^{*ab} Yuxiu Liu,^{*a} Yongqiang Li,^a and Qingmin Wang^{*a}

Herein, we report a new, efficient and atom-economical strategy for the synthesis of SCF₃-substituted tryptanthrin derivatives. These previously unreported derivatives were obtained by means of a radical tandem cyclization. The reaction was triggered by addition of SCF₃ radical to a carbon–carbon double bond and involved the formation of a C(sp³)–SCF₃ bond, a C(sp²)–C bond, and a C(sp²)–N bond. This method has a mild condition and a wide range of substrates which is particularly useful for the preparation of substituted indolquinazoline derivatives that widely exists in many natural products, but are not easy to obtain in conventional approaches.

Introduction

Published on 24 February 2020. Downloaded by Imperial College London Library on 2/24/2020 9:16:34 PM

The alkaloid tryptanthrin consists of a quinazoline ring fused to an indole moiety with carbonyl groups at the 6- and 12-positions (Figure 1). This compound can be isolated from *Polygonum tinctorium Lour*, *Strobilanthes cusia*, and *Isatis tinctoria*,¹ which are sources of blue dyes and were also used to treat cuts, infections, and hemorrhoids in ancient China. In addition, tryptanthrin has recently been found to have a broad spectrum of biological activities, including antitumor activity,² antifungal activity,³ and antituberculotic activity.⁴ Therefore, a large number of tryptanthrin derivatives, both naturally occurring and chemically synthesized, have been studied. These derivatives can be divided into two main types: one type containing various substituents on the two benzene rings⁵ and a second type in which the C6 carbonyl group has been replaced by some other functional group⁶ (Figure 1). It was found that the C6 substituted tryptamine showed better biological activity.

Tryptanthrin derivatives are generally prepared by reactions of substituted isatoic anhydrides and isatins^{5c} (Figure 2a), but the necessary substituted isatoic anhydrides are not always easy to prepare. Another approach involves oxone-induced dimerization of indole-3-carbaldehydes^{5b} (Figure 2b), but this method can be used only with indoles bearing a halogen atom at the 5-position of the aryl ring. In addition, Wang et al. reported a copper-catalyzed synthesis of tryptanthrins from substituted indoles^{5e} (Figure 2c); however, the process is operationally complicated, and the yields are only

moderate. Tryptanthrin analogues can also be synthesized via aldol reactions between tryptanthrin and various ketones^{6a,7} (Figure 2d), and reactions of primary amines with the C6 carbonyl group of tryptanthrin afford Schiff base analogues^{6b} (Figure 2e). Although significant achievements have been made for the synthesis of tryptanthrin derivatives, mild and efficient synthetic approaches for synthesis of C6 substituted tryptanthrin derivatives remain to be further developed.



Figure 1. Structure of tryptanthrin and the two main types of derivatives.

Organofluorine chemistry has been garnering increasing attention because of its applications in drug development, pesticide chemistry, and materials technology.⁸ In particular, various research groups have recently focused on the trifluoromethylthio group (CF₃S) owing to its electronic properties, high stability, and lipophilicity.⁹ This functional group has been shown to improve the membrane permeability and bioavailability of molecules containing it.¹⁰ Various trifluoromethylthiolation reagents have been reported, and the use of AgSCF₃ is a straightforward method for accomplishing trifluoromethylthiolation/cyclization reactions via radical,¹¹ anionic,¹² and cationic pathways.¹³ Nevertheless, methods for direct

^a State Key Laboratory of Elemento-Organic Chemistry, Research Institute of Elemento-Organic Chemistry, College of Chemistry, Collaborative Innovation Center of Chemical Science and Engineering (Tianjin), Nankai University Tianjin 300071 (China).E-mail: <u>wangam@nankai.edu.cn</u>; E-mail: liuyuxiu@nankai.edu.cn

^{b.} Tianjin Key Laboratory of Structure and Performance for Functional Molecules, College of Chemistry, Tianjin Normal University, Tianjin 300387 (P. R. China). Email: <u>hxxywzw@tjnu.edu.cn</u>

[#] Guo and Hao contributed equally to this work.

Electronic Supplementary Information (ESI) available: [details of any supplementary information available should be included here]. See DOI: 10.1039/x0xx00000x

construction of common heterocyclic scaffolds while simultaneously incorporating a trifluoromethylthio group would be highly desirable.

N-Acyl cyanamide could be used as an effective radical acceptor for heterocycles synthesis.¹⁴ Inspired by this and as the continuation of our efforts in heterocycles synthesis,¹⁵ we synthesized a series of trifluoromethylthio-substituted tryptanthrin derivatives by means of a single-step protocol involving a direct trifluoromethylthiolation/cyclization cascade reaction (Figure 2f). This method is particularly useful for the preparation of substituted indolquinazoline derivatives which widely exists in many natural products, but are not easy to obtain in conventional approaches.

a) Synthesis using substituted isatins and isatoic anhydrides

ARTICLE



b) Synthesis using oxone-induced dimerization of indole-3-carbaldehydes



c) Copper-catalyzed synthesis of tryptanthrin from substituted indoles (Wang' work)



d) Synthesis of tryptanthrin derivatives by aldol reaction



e) Synthesis of Schiff base analogues of tryptanthrin



f) Synthesis of tryptanthrin derivatives by radical cascade cyclization (this work)



Figure 2. Previously reported strategies for the synthesis of tryptanthrin derivatives and our new approach to the synthesis of trifluoromethylthio-substituted tryptanthrins.

Results and discussion

We set out to obtain trifluoromethylthio-substituted tryptanthrin **2a** from *N*-acylcyanamide **1a** (0.2 mmol) by reaction with AgSCF₃ (1.2 equiv) and $K_2S_2O_8$ (2.0 equiv) in DMSO under air at 60 °C for 16 h; and we were pleased to find that these conditions did in fact afford 2a, in a yield of 92% as indicated by ¹H NMR spectroscopy (Table 1, entry 1). Subsequently, we evaluated the effects of decreasing the amount of oxidant (entries 2 and 3) and changing the oxidant to benzoyl peroxide, iodobenzene diacetate, ceric sulfate, or a peroxosulphate

(entries 4–8); these experiments revealed that 1.5 equivAQELK2S2Q8 was optimal. Screening of various solvents 2^{-1} of the 30 of 10 of 20 of

Table 1. Optimization of the reaction conditions.^[a]



entry	oxidant (equiv)	solvent	yield (%) ^[b]
1	$K_2S_2O_8(2.0)$	DMSO	92
2	$K_2S_2O_8(1.5)$	DMSO	95 (86 ^[c])
3	$K_2S_2O_8(1.0)$	DMSO	84
4	benzoyl peroxide (1.5)	DMSO	NR
5	PhI(OAc) ₂ (1.5)	DMSO	trace
6	Ce(SO ₄) ₂ (1.5)	DMSO	trace
7	$(NH_4)_2S_2O_8(1.5)$	DMSO	79
8	$Na_2S_2O_8(1.5)$	DMSO	81
9	$K_2S_2O_8(1.5)$	CH₃CN	66
10	$K_2S_2O_8(1.5)$	DMF	17
11	$K_2S_2O_8(1.5)$	DCE	NR
12	$K_2S_2O_8(1.5)$	THF	NR
13	$K_2S_2O_8(1.5)$	dioxane	NR
14	$K_2S_2O_8(1.5)$	toluene	NR
15	$K_2S_2O_8(1.5)$	acetone	NR

^[a] Reaction conditions: 1a (0.2 mmol), AgSCF₃ (0.24 mmol, 1.2 equiv), oxidant (1.0–2.0 equiv), 2 mL solvent, at 60 °C under air for 16 h. ^[b] Determined by ¹H NMR spectroscopy with CH_2Br_2 as an internal standard. ^[c] Isolated yield. NR = no reaction.

With the optimized conditions in hand (Table 1, entry 2), we explored the generality of the protocol by carrying out reactions of various substrates 1. We began by evaluating the effects of substituents on the phenyl ring attached to the carbonyl group (Scheme 1). Substrates with an electron-withdrawing group (**1b–1e**) or an electron-donating group (**1f–1h**, **1k**) in the *para* position afforded the corresponding products in 70–86% yields. Comparison of the yields of methyl-substituted products **2f**, **2i**, and **2j** indicated that the position of the methyl group had little effect; however, when the methyl substituent was in the *meta* position of the phenyl ring, there were two sites at which the ring could undergo attack by the imine radical generated during the reaction, so two regioisomers, **2i-1** and

2i-2, were obtained in a 1:2.5 ratio. Replacing the phenyl group with naphthyl group also gave the desired product (**2l**) in good yield (72%).



Scheme 1. Synthesis of trifluoromethylthio-substituted tryptanthrins **2b–2l**. Unless otherwise noted, all reactions were performed with **1** (0.2 mmol, 1 equiv), AgSCF₃ (1.2 equiv), and $K_2S_2O_8$ (1.5 equiv) in DMSO (2 mL) at 60 °C under air for 16 h. Isolated yields are given.





2p 81%



Next, we explored the effects of substituents on the phenyl ring attached to the amide nitrogen (Scheme 2). Electron-withdrawing

groups had a negligible effect on the yields (**2m**, **2n**), but a substrate with two electron-donating methoxy groups: did OABCD aff8P02tRe corresponding product (**2o**). Furthermore, when the 2-phenylpropene moiety of the substrate was replaced with an alkyl chain bearing a terminal olefin, **2p** was obtained in 81% yield.

Finally, we investigated the effects of the R^3 substituent on the carbon–carbon double bond (Scheme 3). When the substituent was an isopropyl group, the yield of **2q** was only 57%; but products with a long-chain alkyl group (**2s**), a cycloalkyl group (**2r**), or an aryl group (**2t–2x**) could be obtained in 80–84% yields. However, when R^3 was a hydrogen atom, none of the desired product (**2y**) was detected; the double bond of **1y** may have oxidized or polymerized.





Scheme 3. Synthesis of trifluoromethylthio-substituted tryptanthrins 2q–2x. The reaction conditions are described in Scheme 1.



Scheme 4. Mechanistic experiments.

Two control experiments were conducted to probe the reaction mechanism (Scheme 4). When an *N*-acylcyanamide with a chlorine atom at each of the two *ortho* positions of the phenyl ring attached to the carbonyl carbon was subjected to the standard conditions, a

product **2z** generated by the loss of one of the chlorine atoms was obtained in 84% yield, a result that rules out a mechanism involving

ARTICLE

obtained in 84% yield, a result that rules out a mechanism involving cyclization of an imine cation. Specifically, the addition of the radical scavenger TEMPO completely inhibited the reaction. We recovered **1a** with 96% yield. The corresponding product **2aa** and the directing trapping product between TEMPO and SCF3 radical were not observed based on ¹H NMR and HRMS.

On the basis of the above-described experiments and relevant literature precedents, a plausible mechanism is depicted in Scheme 5. First, oxidation of AgSCF₃ by $K_2S_2O_8$ gives the SCF₃ radical, which adds to the carbon–carbon double bond of substrate **1a** to give benzyl radical intermediate **A**. Intermediate **A** undergoes subsequent 5-*exo-dig* cyclization to generate imine radical intermediate **B**, and then 6-*endo-tig* cyclization affords phenyl radical intermediate **C**. Finally, oxidation of **C** produces cationic intermediate **D**, which undergoes deprotonation to generate **2a**.



Scheme 5. Proposed reaction mechanism.

Experimental

Published on 24 February 2020. Downloaded by Imperial College London Library on 2/24/2020 9:16:34 PM

General Experimental Details. Reagents were purchased from commercial sources and were used as received. ¹H and ¹³C Nuclear Magnetic Resonance (NMR) spectra were recorded on Bruker Avance 400 Ultrashield NMR spectrometers. Chemical shifts (δ) were given in parts per million (ppm) and were measured downfield from internal tetramethylsilane. High-resolution mass spectrometry (HRMS) data were obtained on an FTICR-MS instrument (Ionspec 7.0 T). The melting points were determined on an X-4 microscope melting point apparatus and are uncorrected. Conversion was monitored by thin layer chromatography (TLC). Flash column chromatography was performed over silica gel (100-200 mesh). The preparation of substrates **1** can be seen in Supporting Information.

General procedures for the condition optimization.

To a 25 mL over-dried shrek tube was added **1a** (52.4 mg, 0.2 mmol, 1.0 equiv), AgSCF₃ (50.4 mg, 0.24 mmol, 1.2 equiv), corresponding oxidant (1.0–2.0 equiv) and 2.0 mL corresponding solvent. The reaction mixture was stirred rapidly at 60 °C for 16 h. The mixture was diluted with brine (40 mL), and extracted with EA (40 mL \times 3).

The combined organic extracts were washed with brine, (40 mL), dried over Na₂SO₄, and concentrated in vacua. The vacual of the vacuation of the vacuation

General procedures for the synthesis of 2a-2x.

To a 25 mL over-dried shrek tube was added **1** (0.2 mmol, 1.0 equiv) AgSCF₃ (0.24 mmol, 1.2 equiv), $K_2S_2O_8$ (0.3 mmol, 1.5 equiv) and 2.0 mL DMSO. The reaction mixture was stirred rapidly at 60 °C for 16 h. The mixture was diluted with brine (40 mL), and extracted with EA (40 mL × 3). The combined organic extracts were washed with brine (40 mL), dried over Na₂SO₄, and concentrated in vacuo. The residue was purified by flash chromatography on silica gel using the PE/EA system to afford the desired products **2a–2x**.

6-Methyl-6-(((trifluoromethyl)thio)methyl)indolo[2,1-b]quinazolin-12(6*H*)-one (**2a**). White solid, 86% yield, mp: 97-98 °C, ¹H NMR (400 MHz, CDCl₃) δ 8.62 (d, *J* = 8.0 Hz, 1H), 8.43 (d, *J* = 7.9 Hz, 1H), 7.79 (d, *J* = 3.7 Hz, 2H), 7.57 – 7.45 (m, 3H), 7.37 (t, *J* = 7.5 Hz, 1H), 3.61 (q, *J* = 12.9 Hz, 2H), 1.76 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 161.2, 159.8, 147.3, 139.3, 134.5, 133.1, 130.4 (q, *J* = 307.8 Hz), 129.6, 127.5, 127.2, 126.9, 126.8, 123.0, 121.6, 117.4, 48.7, 38.60 (q, *J* = 2.0 Hz), 25.1. HRMS (ESI) calcd for $C_{18}H_{14}F_{3}N_2OS$ [M+H]⁺ 363.0773, found 363.0776.

3-Fluoro-6-methyl-6-(((trifluoromethyl)thio)methyl)indolo[2,1-

b]quinazolin-12(6*H*)-one (**2b**). White solid, 86% yield, mp: 106-107 °C, ¹H NMR (400 MHz, CDCl₃) δ 8.59 (d, J = 8.0 Hz, 1H), 8.45 – 8.39 (m, 1H), 7.53 – 7.35 (m, 4H), 7.30 – 7.21 (m, 1H), 3.60 (q, J = 12.9 Hz, 2H), 1.75 (s, 4H). ¹³C NMR (100 MHz, CDCl₃) δ 166.5 (d, J = 254.8 Hz), 162.6, 159.1, 149.5 (d, J = 13.1 Hz), 139.2, 133.0, 130.3 (q, J = 306.7 Hz), 129.7, 129.6 (d, J = 10.7 Hz), 126.9, 123.0, 118.2, 117.4, 115.8 (d, J = 23.3 Hz), 113.1 (d, J = 22.2 Hz), 48.9, 38.5 (q, J = 2.0 Hz), 25.0. HRMS (ESI) calcd for C₁₈H₁₄F₄N₂OS [M+H]⁺ 381.0679, found 381.0675.

3-Chloro-6-methyl-6-(((trifluoromethyl)thio)methyl)indolo[2,1b]quinazolin-12(6*H*)-one (**2c**). White solid, 84% yield, mp: 140-141 °C, ¹H NMR (400 MHz, CDCl₃) δ 8.60 (t, *J* = 6.6 Hz, 1H), 8.35 (d, *J* = 8.5 Hz, 1H), 7.79 (d, *J* = 1.9 Hz, 1H), 7.55 – 7.44 (m, 3H), 7.43 – 7.36 (m, 1H), 3.60 (q, *J* = 12.9 Hz, 2H), 1.74 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 162.5, 159.3, 148.2, 139.1, 133.0, 130.5, 130.3, 130.2 (q, *J* = 306.7 Hz), 129.7, 129.2, 128.3, 127.0, 123.0, 120.4, 117.4, 48.9, 38.5(q, *J* = 2.0 Hz), 25.0. HRMS (ESI) calcd for C₁₈H₁₃ClF₃N₂OS [M+H]⁺ 397.0384, found 397.0384.

3-Bromo-6-methyl-6-(((trifluoromethyl)thio)methyl)indolo[2,1-

b]quinazolin-12(6*H*)-one (**2d**). White solid, 70% yield, mp: 159-161 °C, ¹H NMR (400 MHz, CDCl₃) δ 8.59 (d, *J* = 8.1 Hz, 1H), 8.28 (d, *J* = 8.5 Hz, 1H), 7.98 (d, *J* = 1.8 Hz, 1H), 7.65 (dd, *J* = 8.5, 1.9 Hz, 1H), 7.56 – 7.44 (m, 2H), 7.39 (t, *J* = 7.5 Hz, 1H), 3.59 (q, *J* = 12.9 Hz, 2H), 1.74 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 162.5, 159.3, 148.2, 139.1, 133.0, 130.5, 130.3, 130.2 (q, *J* = 306.7 Hz), 129.7, 129.2, 128.3, 127.0, 123.0, 120.4, 117.4, 48.9, 38.5(q, *J* = 2.0 Hz), 25.0. HRMS (ESI) calcd for C₁₈H₁₃BrF₃N₂OS [M+H]⁺ 440.9879, found 440.9872.

6-Methyl-12-oxo-6-(((trifluoromethyl)thio)methyl)-6,12-

dihydroindolo[2,1-b]quinazoline-3-carbonitrile (**2e**). White solid, 84% yield, mp: 127-128 °C, ¹H NMR (400 MHz, CDCl₃) δ 8.59 (d, *J* = 8.0 Hz, 1H), 8.52 (d, *J* = 8.2 Hz, 1H), 8.11 (d, *J* = 0.9 Hz, 1H), 7.78 – 7.70

(m, 1H), 7.60 – 7.38 (m, 3H), 3.62 (q, J = 13.1 Hz, 2H), 1.76 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 163.2, 158.5, 147.2, 138.8, 133.0, 132.2, 130.2 (q, J = 306.7 Hz), 129.9, 129.0, 128.2, 127.4, 124.6, 123.1, 117.8, 117.6, 117.5, 49.2, 38.4 (q, J = 1.8 Hz), 25.0. HRMS (ESI) calcd for C₁₉H₁₃F₃N₃OS [M+H]⁺ 388.0726, found 388.0719.

3,6-Dimethyl-6-(((trifluoromethyl)thio)methyl)indolo[2,1-

b]quinazolin-12(6*H*)-one (**2f**). White solid, 84% yield, mp: 131-132 °C, ¹H NMR (400 MHz, CDCl₃) δ 8.62 (d, *J* = 8.1 Hz, 1H), 8.31 (d, *J* = 8.1 Hz, 1H), 7.59 (s, 1H), 7.52 – 7.44 (m, 2H), 7.40 – 7.35 (m, 2H), 3.59 (q, *J* = 12.8 Hz, 2H), 2.54 (s, 3H), 1.74 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 161.2, 159.9, 147.4, 145.6, 139.4, 133.1, 129.6, 128.7, 127.4, 126.8, 126.6, 123.0, 119.1, 117.3, 48.6, 38.62 (q, *J* = 1.6 Hz), 25.1, 21.9. HRMS (ESI) calcd for C₁₉H₁₆F₃N₂OS [M+H]⁺ 377.0930, found 377.0932.

3-Methoxy-6-methyl-6-(((trifluoromethyl)thio)methyl)indolo[2,1-

b]quinazolin-12(6*H*)-one (**2g**). White solid, 82% yield, mp: 137-138 °C, ¹H NMR (400 MHz, CDCl₃) δ 8.62 (d, *J* = 8.0 Hz, 1H), 8.32 (d, *J* = 8.8 Hz, 1H), 7.58 – 7.43 (m, 2H), 7.38 (t, *J* = 7.5 Hz, 1H), 7.20 (d, *J* = 2.3 Hz, 1H), 7.12 (dd, *J* = 8.8, 2.4 Hz, 1H), 3.97 (s, 3H), 3.61 (q, *J* = 12.9 Hz, 2H), 1.77 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 164.8, 162.0, 159.5, 149.6, 139.5, 130.4 (q, *J* = 306.8 Hz), 133.0, 129.6, 128.4, 126.5, 122.9, 117.3, 117.0, 114.9, 108.5, 55.8, 48.6, 38.6 (q, *J* = 1.2 Hz), 25.0. HRMS (ESI) calcd for C₁₉H₁₆F₃N₂O₂S [M+H]⁺ 393.0879, found 393.0881.

3-(Tert-butyl)-6-methyl-6-(((trifluoromethyl)thio)methyl)indolo[2,1b]quinazolin-12(6*H*)-one (**2h**). White solid, 86% yield, mp: 140-141 °C, ¹H NMR (400 MHz, CDCl₃) δ 8.62 (d, *J* = 8.0 Hz, 1H), 8.35 (d, *J* = 8.4 Hz, 1H), 7.78 (s, 1H), 7.61 (d, *J* = 8.4 Hz, 1H), 7.56 – 7.43 (m, 2H), 7.36 (t, *J* = 7.5 Hz, 1H), 3.60 (q, *J* = 12.8 Hz, 2H), 1.75 (s, 3H), 1.43 (s, 9H). ¹³C NMR (100 MHz, CDCl₃) δ 161.2, 159.8, 158.7, 147.3, 139.4, 133.1, 130.4 (q, *J* = 306.8 Hz), 129.6, 126.6, 126.5, 125.3, 123.8, 123.0, 119.0, 117.3, 48.6, 38.6(q, *J* = 1.6 Hz), 35.5, 31.1, 25.1. HRMS (ESI) calcd for C₂₂H₂₂F₃N₂OS [M+H]⁺ 419.1399, found 419.1401.

2,6-Dimethyl-6-(((trifluoromethyl)thio)methyl)indolo[2,1-

b]quinazolin-12(6*H*)-one (**2i-1**). White solid, 23% yield, mp: 88-99 °C, ¹H NMR (400 MHz, CDCl₃) δ 8.63 (d, *J* = 8.0 Hz, 1H), 8.22 (s, 1H), 7.68 (d, *J* = 8.2 Hz, 1H), 7.61 (d, *J* = 7.9 Hz, 1H), 7.55 – 7.43 (m, 2H), 7.37 (t, *J* = 7.4 Hz, 1H), 3.59 (q, *J* = 12.8 Hz, 2H), 2.53 (s, 3H), 1.74 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 160.3, 159.9, 145.3, 139.4, 137.4, 135.8, 133.2, 130.4 (q, *J* = 306.6 Hz), 129.6, 127.3, 126.6, 126.4, 123.0, 121.3, 117.4, 48.5, 38.7 (q, *J* = 1.5 Hz), 25.0, 21.3. HRMS (ESI) calcd for C₁₉H₁₆F₃N₂OS [M+H]⁺ 377.0930, found 377.0930.

4,6-Dimethyl-6-(((trifluoromethyl)thio)methyl)indolo[2,1-

b]quinazolin-12(6*H*)-one (**2i-2**). White solid, 57% yield, mp: 129-130 °C, ¹H NMR (400 MHz, CDCl₃) δ 8.63 (d, *J* = 8.0 Hz, 1H), 8.27 (d, *J* = 7.9 Hz, 1H), 7.64 (d, *J* = 7.2 Hz, 1H), 7.54 – 7.32 (m, 4H), 3.59 (dd, *J* = 29.4, 12.8 Hz, 2H), 2.68 (s, 3H), 1.75 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 160.2, 159.7, 145.8, 139.4, 136.2, 135.1, 133.4, 130.5 (q, *J* = 306.6 Hz), 129.6, 126.6, 124.5, 123.0, 121.5, 117.4, 48.6, 38.6 (q, *J* = 1.5 Hz), 25.3, 17.4. HRMS (ESI) calcd for C₁₉H₁₆F₃N₂OS [M+H]⁺ 377.0930, found 377.0928.

1,6-Dimethyl-6-(((trifluoromethyl)thio)methyl)indolo[2,1-

b]quinazolin-12(6*H*)-one (**2j**). White solid, 85% yield, mp: 114-115 °C, ¹H NMR (400 MHz, CDCl₃) δ 8.62 (d, *J* = 8.1 Hz, 1H), 7.62 (d, *J* = 4.4 Hz, 2H), 7.51 – 7.43 (m, 2H), 7.36 (t, *J* = 7.5 Hz, 1H), 7.28 (t, *J* = 4.3 Hz,

1H), 3.58 (q, J = 12.8 Hz, 2H), 2.98 (s, 3H), 1.73 (s, 3H). $\frac{13}{120}$ MMR(100 MHz, CDCl₃) δ 160.8, 160.7, 148.9, 141.7, 139%; 133%9/137.0933%, found 377.0935.

6-Methyl-3-phenyl-6-(((trifluoromethyl)thio)methyl)indolo[2,1b]quinazolin-12(6*H*)-one (**2k**). White solid, 82% yield, mp: 122-123 °C, ¹H NMR (400 MHz, CDCl₃) δ 8.67 (d, *J* = 8.0 Hz, 1H), 8.50 (d, *J* = 8.3 Hz, 1H), 8.05 (d, *J* = 1.5 Hz, 1H), 7.82 (dd, *J* = 8.3, 1.6 Hz, 1H), 7.77 (d, *J* = 7.3 Hz, 2H), 7.57 – 7.39 (m, 6H), 3.65 (dd, *J* = 28.2, 12.9 Hz, 2H), 1.80 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 161.6, 159.7, 147.7, 147.4, 139.5, 139.4, 133.1, 130.4 (d, *J* = 306.6 Hz), 129.7, 129.1, 128.6, 127.5, 127.5, 126.7, 126.2, 125.6, 123.0, 120.3, 117.4, 48.7, 38.6 (q, *J* = 1.6 Hz), 25.1. HRMS (ESI) calcd for C₂₄H₁₈F₃N₂OS [M+H]⁺ 439.1086, found 439.1089.

8-Methyl-8-(((trifluoromethyl)thio)methyl)benzo[f]indolo[2,1-

b]quinazolin-14(8*H*)-one (**2l**). White solid, 72% yield, mp: 111-112 °C, ¹H NMR (400 MHz, CDCl₃) δ 10.06 (d, *J* = 8.6 Hz, 1H), 8.79 (d, *J* = 8.0 Hz, 1H), 8.15 (d, *J* = 8.8 Hz, 1H), 7.93 (d, *J* = 7.9 Hz, 1H), 7.83 – 7.73 (m, 2H), 7.63 (t, *J* = 7.4 Hz, 1H), 7.58 – 7.44 (m, 2H), 7.38 (t, *J* = 7.4 Hz, 1H), 7.58 – 7.44 (m, 2H), 7.38 (t, *J* = 7.4 Hz, 1H), 3.63 (q, *J* = 12.9 Hz, 2H), 1.78 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 160.5, 149.6, 139.8, 135.9, 133.6, 132.2, 131.3, 130.4 (q, *J* = 306.6 Hz), 129.7, 128.8, 128.4, 127.2, 126.9, 126.8, 126.2, 123.0, 118.0, 115.0 48.8, 38.4 (q, *J* = 1.6 Hz), 24.8. HRMS (ESI) calcd for C₂₂H₁₆F₃N₂OS [M+H]⁺ 413.0930, found 413.0930.

8-Chloro-6-methyl-6-(((trifluoromethyl)thio)methyl)indolo[2,1-

b]quinazolin-12(6*H*)-one (**2m**). White solid, 82% yield, mp: 188-189 °C, ¹H NMR (400 MHz, CDCl₃) δ 8.44 (dd, *J* = 38.2, 7.2 Hz, 2H), 7.92 – 7.39 (m, 5H), 3.58 (dd, *J* = 33.7, 12.8 Hz, 2H), 1.75 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 160.4, 159.6, 147.2, 138.3, 135.3, 134.6, 132.7, 130.2 (q, *J* = 307.1 Hz), 127.6, 127.4, 126.9, 126.4, 121.4, 119.9, 118.8, 48.8, 38.4 (q, *J* = 1.6 Hz), 24.9. HRMS (ESI) calcd for C₁₈H₁₃ClF₃N₂OS [M+H]⁺ 397.0384, found 397.0382.

8-Bromo-6-methyl-6-(((trifluoromethyl)thio)methyl)indolo[2,1-

b]quinazolin-12(6*H*)-one (**2n**). White solid, 80% yield, mp: 175-176 °C, ¹H NMR (400 MHz, CDCl₃) δ 8.55 (d, *J* = 8.5 Hz, 1H), 8.40 (d, *J* = 7.8 Hz, 1H), 7.84 – 7.74 (m, 2H), 7.59 – 7.52 (m, 1H), 7.50 – 7.42 (m, 2H), 3.59 (q, *J* = 13.1 Hz, 2H), 1.75 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 160.6, 159.6, 147.2, 137.8, 135.0, 134.6, 132.3, 130.2 (q, *J* = 306.8 Hz),129.7, 127.6, 127.4, 126.9, 123.5, 121.4, 118.4, 48.8, 38.4(q, *J* = 1.6 Hz), 24.9. HRMS (ESI) calcd for C₁₈H₁₃BrF₃N₂OS [M+H]⁺ 440.9879, found 440.9870.

3-Methyl-3-(((trifluoromethyl)thio)methyl)-2,3-dihydropyrrolo[2,1b]quinazolin-9(1*H*)-one (**2p**). White solid, 81% yield, mp: 44-45 °C, ¹H NMR (400 MHz, CDCl₃) δ 8.31 (d, *J* = 8.0 Hz, 1H), 7.80 – 7.69 (m, 2H), 7.49 (t, *J* = 7.4 Hz, 1H), 4.35 – 4.25 (m, 1H), 4.14 – 4.03 (m, 1H), 3.40 (dd, *J* = 40.1, 13.4 Hz, 2H), 2.49 – 2.39 (m, 1H), 2.20 – 2.12 (m, 1H), 1.53 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 161.8, 160.8, 149.0, 134.28, 130.7 (q, *J* = 306.0 Hz), 127.2, 126.6, 126.4, 120.9, 47.1, 43.2, 37.6 (q, *J* = 1.6 Hz), 31.7, 24.0. HRMS (ESI) calcd for C₁₄H₁₄F₃N₂OS [M+H]⁺ 315.0773, found 315.0775.

6-Isopropyl-6-(((trifluoromethyl)thio)methyl)indolo[2,1-

b]quinazolin-12(6*H*)-one (**2q**). White solid, 85% yield, mp: 96-97 °C, ¹H NMR (400 MHz, CDCl₃) δ 8.68 (d, *J* = 8.0 Hz, 1H), 8.47 (d, *J* = 8.0 Hz, 1H), 7.83 (d, *J* = 3.1 Hz, 2H), 7.63 – 7.51 (m, 2H), 7.47 (d, *J* = 7.2 Hz,

ARTICLE

1H), 7.40 (t, *J* = 7.4 Hz, 1H), 3.76 (q, *J* = 12.3 Hz, 2H), 2.58 (dt, *J* = 13.6, 6.8 Hz, 1H), 1.03 (d, *J* = 6.9 Hz, 3H), 0.85 (d, *J* = 6.7 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 160.5, 159.8, 147.2, 140.5, 134.4, 130.6, 130.4 (q, *J* = 306.3 Hz), 129.6, 127.7, 127.1, 126.9, 126.4, 123.8, 121.5, 117.2, 56.0, 37.5, 36.2 (q, *J* = 1.5 Hz), 17.3. HRMS (ESI) calcd for C₂₀H₁₈F₃N₂OS [M+H]⁺ 391.1086, found 391.1085.

6-Cyclohexyl-6-(((trifluoromethyl)thio)methyl)indolo[2,1-

b]quinazolin-12(6*H*)-one (**2r**). White solid, 82% yield, mp: 145-146 °C, ¹H NMR (400 MHz, CDCl₃) δ 8.68 (d, *J* = 8.0 Hz, 1H), 8.47 (d, *J* = 7.9 Hz, 1H), 7.91 – 7.78 (m, 2H), 7.63 – 7.51 (m, 2H), 7.47 (d, *J* = 7.2 Hz, 1H), 7.40 (t, *J* = 7.5 Hz, 1H), 3.84 – 3.68 (m, 2H), 2.24 (t, *J* = 11.8 Hz, 1H), 1.79 (t, *J* = 12.0 Hz, 2H), 1.63 (s, 2H), 1.43 (d, *J* = 12.3 Hz, 1H), 1.30 – 1.14 (m, 3H), 1.08 – 0.94 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 160.8, 159.8, 147.2, 140.5, 134.4, 131.0, 130.5 (q, *J* = 306.7 Hz), 129.5, 127.7, 127.1, 126.9, 126.4, 123.9, 121.4, 117.1, 56.2, 47.4, 35.9 (q, *J* = 1.1 Hz), 27.2, 26.4, 26.1, 25.9. HRMS (ESI) calcd for C₂₃H₂₂F₃N₂OS [M+H]⁺ 431.1339, found 431.1394.

6-Pentyl-6-(((trifluoromethyl)thio)methyl)indolo[2,1-b]quinazolin-

12(6*H*)-one (**2s**). White solid, 80% yield, mp: 57-58 °C, ¹H NMR (400 MHz, CDCl₃) δ 8.64 (d, *J* = 8.0 Hz, 1H), 8.44 (d, *J* = 7.9 Hz, 1H), 7.80 (d, *J* = 3.7 Hz, 2H), 7.62 – 7.47 (m, 2H), 7.45 – 7.32 (m, 2H), 3.61 (dd, *J* = 32.1, 12.7 Hz, 2H), 2.37 – 2.20 (m, 1H), 2.13 – 1.97 (m, 1H), 1.12 (s, 4H), 0.94 – 0.76 (m, 2H), 0.77 – 0.67 (m, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 160.5, 159.8, 147.3, 140.2, 134.4, 131.6, 130.4 (q, *J* = 306.6 Hz), 129.6, 127.6, 127.1, 126.9, 126.7, 123.1, 121.5, 117.3, 53.1, 39.0, 38.2(q, *J* = 1.6 Hz), 31.6, 29.7, 23.8, 22.1, 13.8. HRMS (ESI) calcd for C₂₂H₂₂F₃N₂OS [M+H]⁺ 419.1399, found 419.1398.

6-Phenyl-6-(((trifluoromethyl)thio)methyl)indolo[2,1-b]quinazolin-12(6*H*)-one (**2t**). White solid, 81% yield, mp: 41-43 °C, ¹H NMR (400 MHz, CDCl₃) δ 8.71 (d, *J* = 8.1 Hz, 1H), 8.41 (d, *J* = 7.7 Hz, 1H), 7.79 – 7.73 (m, 2H), 7.61 – 7.48 (m, 3H), 7.47 – 7.40 (m, 3H), 7.37 – 7.27 (m, 3H), 4.12 (dd, *J* = 40.4, 12.4 Hz, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 160.0, 159.9, 147.3, 140.2, 139.0, 134.5, 131.9, 131.5, 130.1, 129.0, 128.4, 127.9, 127.3, 127.0, 126.9, 126.8, 125.2, 121.5, 117.6, 56.1, 38.2 (q, *J* = 1.6 Hz). HRMS (ESI) calcd for C₂₃H₁₆F₃N₂OS [M+H]⁺ 425.0930, found 425.0934.

6-(4-Fluorophenyl)-6-(((trifluoromethyl)thio)methyl)indolo[2,1-

b]quinazolin-12(6*H*)-one (**2u**). White solid, 82% yield, mp: 91-92 °C, ¹H NMR (400 MHz, CDCl₃) δ 8.76 – 8.67 (m, 1H), 8.42 (d, *J* = 7.7 Hz, 1H), 7.82 – 7.73 (m, 2H), 7.63 – 7.58 (m, 1H), 7.57 – 7.52 (m, 1H), 7.50 (d, *J* = 6.5 Hz, 1H), 7.47 – 7.44 (m, 1H), 7.44 – 7.38 (m, 2H), 7.35 – 7.28 (m, 2H), 4.07 (dd, *J* = 31.4, 12.5 Hz, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 163.8, 161.3, 159.8 (d, *J* = 2.6 Hz), 147.2, 140.2, 134.5, 131.1, 130.3, 129.1, 129.0 (d, *J* = 8.2 Hz), 128.5, 127.8, 127.4, 126.9, 126.8, 125.2, 121.5, 117.7, 115.9 (d, *J* = 21.6 Hz), 55.5, 38.5 (q, *J* = 1.3 Hz). HRMS (ESI) calcd for C₂₃H₁₅F₄N₂OS [M+H]⁺ 443.0836, found 443.0840.

6-(4-Chlorophenyl)-6-(((trifluoromethyl)thio)methyl)indolo[2,1b]quinazolin-12(6*H*)-one (**2v**). White solid, 83% yield, mp: 183-184 °C, ¹H NMR (400 MHz, CDCl₃) δ 8.71 (d, *J* = 8.1 Hz, 1H), 8.41 (d, *J* = 7.7 Hz, 1H), 7.79 – 7.75 (m, 2H), 7.62 – 7.56 (m, 1H), 7.56 – 7.51 (m, 1H), 7.51 – 7.47 (m, 1H), 7.47 – 7.43 (m, 1H), 7.43 – 7.38 (m, 2H), 7.34 – 7.28 (m, 2H), 4.07 (dd, *J* = 31.4, 12.5 Hz, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 159.8, 159.5, 147.1, 140.2, 137.4, 134.6, 134.5, 130.9, 130.3, 129.1, 128.5, 127.8, 127.4, 127.2 (q, *J* = 306.9 Hz), 126.9, 126.8,

125.1, 121.4, 117.7, 55.6, 38.3 (q, J = 1.3 Hz). HRMS ([ESI], galed, for C₂₃H₁₅ClF₃N₂OS [M+H]⁺ 459.0540, found 459.053 \Re .1039/D00B00233J

6-(4-Bromophenyl)-6-(((trifluoromethyl)thio)methyl)indolo[2,1-

b]quinazolin-12(6*H*)-one (**2w**). White solid, 80% yield, mp: 160-161 °C, ¹H NMR (400 MHz, CDCl₃) δ 8.71 (d, *J* = 8.1 Hz, 1H), 8.41 (d, *J* = 7.9 Hz, 1H), 7.85 – 7.71 (m, 2H), 7.59 (t, *J* = 7.7 Hz, 1H), 7.57 – 7.51 (m, 1H), 7.50 – 7.39 (m, 4H), 7.34 (d, *J* = 8.6 Hz, 2H), 4.06 (dd, *J* = 30.7, 12.4 Hz, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 159.8, 159.4, 147.1, 140.2, 137.9, 134.6, 132.1, 130.9, 130.4, 128.8, 127.8, 127.5, 126.9, 126.9, 125.1, 122.8, 121.4, 117.7, 100.0, 55.6, 38.2 (q, *J* = 1.5 Hz). HRMS (ESI) calcd for C₂₃H₁₅BrF₃N₂OS [M+H]⁺ 503.0335, found 503.0335.

6-(*p*-Tolyl)-6-(((trifluoromethyl)thio)methyl)indolo[2,1-b]quinazolin-12(6*H*)-one (**2x**). White solid, 84% yield, mp: 126-127 °C, ¹H NMR (400 MHz, CDCl₃) δ 8.71 (d, *J* = 8.0 Hz, 1H), 8.40 (d, *J* = 7.8 Hz, 1H), 7.78 – 7.70 (m, 2H), 7.59 – 7.46 (m, 3H), 7.41 (t, *J* = 7.5 Hz, 1H), 7.32 (d, *J* = 8.2 Hz, 2H), 7.14 (d, *J* = 8.1 Hz, 2H), 4.10 (q, *J* = 12.4 Hz, 2H), 2.30 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 159.9, 147.3, 140.2, 138.4, 136.1, 134.4, 131.8, 130.4 (d, *J* = 306.9 Hz), 130.0, 129.7, 127.9, 127.2, 126.9, 126.8, 126.7, 125.2, 121.5, 117.5, 55.8, 38.2 (q, *J* = 1.5 Hz), 21.0. HRMS (ESI) calcd for C₂₄H₁₈F₃N₂OS [M+H]⁺ 439.1086, found 439.1085.

Verify experiment (Scheme 4), preparation of 1-chloro-6-methyl-6-(((trifluoromethyl)thio)methyl)indolo[2,1-b]quinazolin-12(6H)-one (2z).

To a 25 mL over-dried shrek tube was added 1z (83.4 mg, 0.2 mmol, 1.0 equiv), AgSCF₃ (50.4 mg, 0.24 mmol, 1.2 equiv), $K_2S_2O_8$ (81 mg, 0.3 mmol, 1.5 equiv) and 2.0 mL DMSO. The reaction mixture was stirred rapidly at 60 °C for 16 h. Compound **2z** was isolated in 84% yield, white solid, mp: 69-71 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.66 (d, J = 7.7 Hz, 1H), 7.54 – 7.40 (m, 3H), 7.36 (d, J = 7.1 Hz, 1H), 6.68 (d, J = 7.0 Hz, 2H), 3.56 (s, 2H), 1.81 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 181.4, 179.0, 167.7, 146.5, 146.4, 136.1, 134.0, 130.4, 130.3 (q, J = 348.1 Hz), 130.1 127.0, 124.4, 113.5, 45.1, 37.2 (q, J = 2.1 Hz), 24.5. HRMS (ESI) calcd for C₁₈H₁₃ClF₃N₂OS [M+H]⁺ 397.0348, found 397.0380.

TEMPO were used as radical scavenger (Scheme 4).

To a 25 mL over-dried shrek tube was added 1a (52.4 mg, 0.2 mmol, 1.0 equiv), AgSCF₃ (50.4 mg, 0.24 mmol, 1.2 equiv), TEMPO (62.5 mg, 0.4 mmol, 2.0 equiv), $K_2S_2O_8$ (0.3 mmol, 1.5 equiv) and 2.0 mL DMSO. The reaction mixture was stirred rapidly at 60 °C for 16 h. We recovered **1a** with 96% yield. The corresponding product **2aa** and the directing trapping product between TEMPO and SCF₃ radical were not observed based on ¹H NMR and HRMS.

Conclusions

In short, we used *N*-acylcyanamides as starting materials for the synthesis of previously unreported trifluoromethylthiosubstituted tryptanthrin derivatives by means of a radical trifluoromethylthiolation/cyclization cascade. This transformation, which involves the formation of a $C(sp^3)$ –SCF₃ bond, a $C(sp^2)$ –C bond, and a $C(sp^2)$ –N bond, proceeds smoothly in moderate to excellent yields and represents a new strategy for synthesis of tryptanthrin derivatives.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This study was supported by Natural Science Fund of China (21772145, 21732002, 21772104).

Notes and references

- a) G. Honda, M. Tabata, *Planta Med.*, 1979, **36**, 85–86; b) G. Honda, V. Tosirisuk, M. Tabata, *Planta Med.*, 1980, **38**, 275– 276; c) D. Henning, B. Dietmar, H. Matthias, *Planta Med.*, 2002, **68**, 152–157.
- 2 a) V. M. Sharma, P. Prasanna, K. V. A. Seshu, B. Renuka, C. V. L. Rao, G. S. Kumar, C. P. Narasimhulu, P. A. Babu, R. C. Puranik, D. Subramanyama, A. Venkateswarlua, S. Rajagopalb, K. B. S. Kumarb, C. S. Raob, N. V. S. R. Mamidib, D. S. Deevib, R. Ajaykumarb, R. Rajagopalanb, *Bioorg. Med. Chem. Lett.*, 2002, **12**, 2303–2307; b) S. T. Yu, J. W. Chen, T. M. Chen, Y. F. Chiu, H. T. Chen, Y. H. Chen, *Acta Pharmacol. Sin.*, 2010, **31**, 259–264.
- 3 X. Zhu, X. Zhang, G. Ma, J. Yan, H. Wang, Q. Yang, *J. Pharm. Pharm. Sci.*, 2011, **14**, 325–335.
- 4 A. K. Bhattacharjee, M. G. Hartell, D. A. Nichols, R. P. Hicks, B. Stanton. J. E. Hamont, W. K. Milhous, *Eur. J. Med. Chem.*, 2004, **39**, 59–67.
- 5 a) A. Kumar, V. D. Tripathi, P. Kumar, *Green Chem.*, 2011, 13, 51–54; b) A. C. Nelson, E. S. Kalinowski, T. L. Jacobson, P. Grundt, *Tetrahedron Lett.*, 2013, 54, 6804–6806; c) J. K. Son, J. G. Park, Y. Jahng, *Heterocycl. Commun.*, 2003, 9, 621–627; d) J. Bergman, J. O. Lindstrm, U. Tilstam, *Tetrahedron*, 1985, 41, 2879–2881; e) C. Wang, L. P. Zhang, A. N. Ren, P. Lu, Y. G. Wang, *Org. Lett.*, 2013, 15, 2982–2985.
- 6 a) P. I. Deryabin, T. V. Moskovkina, L. S. Shevchenko, A. I. Kalinovskii, *Russ. J. Org. Chem.*, 2017, **53**, 418–422; b) B. L. Hou, Y. Ai, C. L. Wang, N. Zhang, L. Yang, Z. L. Liu, J. L. Liu, *Chin. J. Org. Chem.*, 2016, **36**, 121–129; c) J. Azizian, M. R. Mohammadizadeh, S. Zomorodbakhsh, *Arkivoc*, 2007, **15**, 24–30; d) H. W. Liao, X. J. Peng, D. Hu, X. Y. Xu, P. P. Huang, Q. Liu, L. X. Liu, *Org. Biomol. Chem.*, 2018, **16**, 5699–5760.
- 7 D. Gahtory, M. Chouhan, R. Sharma, V. A. Nair, Org. Lett., 2013, 15, 3942–3945.
- a) M. Egli, Acc. Chem. Res., 2012, 45, 1237–1246; b) R. Littich, P. J. H. Scott, Angew. Chem. Int. Ed., 2012, 51, 1106–1109; c) M. Cametti, B. Crousse, B. P. Metrangolo, R. Milani, G. Resnati, Chem. Soc. Rev., 2012, 41, 31–42; d) M. Salwiczek, E. K. Nyakatura, U. I. M. Gerling, S. J. Ye, B. Koksch, Chem. Soc. Rev., 2012, 41, 2135–2171; e) M. Bremer, P. Kirsch, M. Klasen-Memmer, K. Tarumi, Angew. Chem. Int. Ed., 2013, 52, 8880– 8896; f) T. Nakajima, J. Fluorine Chem., 2013, 149, 104–111; g) J. Wang, M. Sanchez-Rosello, J. L. Acena, C. Pozo, A. E. Sorochinsky, S. Fustero, V. A. Soloshonok, H. Liu, Chem. Rev., 2014, 114, 2432–2506.
- 9 a) X. Shao, C. Xu, L. Lu, Q. Shen, Accounts Chem. Res., 2015, 48, 1227–1236; b) S. Rossi, A. Puglisi, L. Raimondi, M. Benaglia, ChemCatChem, 2018, 10, 2717–2733; c) D. G. Dagousset, D. C. Simon, D. E. Anselmi, D. B. Tuccio, D. T. Billard, D. E. Magnier, Chem. Eur. J., 2017, 23, 4282–4286; c) M. Zhu, R. Li, Q. You, W. Fu, W. Guo, Asian J. Org. Chem., 2019, 8, 2002–2005; d) A. L. Barthelemy, E. Magnier, G. Dagousset, Synthesis, 2018, 50, 4765–4776.
- a) M. Li, B. Zhou, X. S. Xue, J. P. Cheng, J. Org. Chem., 2017, 82, 8697–8702;
 b) M. Li, J. Guo, X. S. Xue, J. P. Cheng, Org. Lett., 2016, 18, 264–267;
 c) Y. Li, T. Koike, M. Akita, Asian J. Org.

Chem., 2017, **6**, 445–448; d) M. Zhu, W. J. Fu, W. S. Guo, Y. F. Tian, Z. Q. Wang, B. M. Ji, *Org. Biomol. <u>Chem.</u>* 2019, **37**, 373–3380.

- 11 a) F. Yin, X. S. Wang, Org. Lett., 2014, 16, 1128–1131; b) L. Zhu, G. Wang, Q. Guo, Z. Xu, D. Zhang, R. Wang, Org. Lett., 2014, 16, 5390–5393; c) N. Fuentes, W. Kong, L. Fernandez-Sanchez, E. Merino, C. Nevado, J. Am. Chem. Soc., 2015, 137, 964-973; d) Y. F. Qiu, X. Y. Zhu, Y. X. Li, Y. T. He, F. Yang, J. Wang, H. L. Hua, L. Zheng, L. C. Wang, X. Y. Liu, Y. M. Liang, Org. Lett., 2015, 17, 3694–3697; e) Y. F. Zeng, D. H. Tan, Y. Chen, W. X. Lv, X. G. Liu, Q. Li, H. Wang, Org. Chem. Front., 2015, 2, 1511-1515; f) D. P. Jin, P. Gao, D. Q. Chen, S. Chen, J. Wang, X. Y. Liu, Y. M. Liang, Org. Lett., 2016, 18, 3486–3489; g) M. T. Chen, X. Y. Tang, M. Shi, Org. Chem. Front., 2017, 4, 86-90; h) S. Pan, Y. G. Huang, X. H. Xu, F. L. Qing, Org. Lett., 2017, 19, 4624-4627; i) K. Guo, H. Zhang, S. Cao, C. Gu, H. Zhou, J. Li, Y. Zhu, Org. Lett., 2018, 20, 2261-2264; j) Y. F. Qiu, Y. J. Niu, X. Wei, B. Q. Cao, X. C. Wang, Z. J. Quan, J. Org. Chem., 2019, 84, 4165-4278.
- 12 a) K. P. Wang, S. Y. Yun, P. Mamidipalli, D. Lee, *Chem. Sci.*, 2013, **4**, 3205–3211; b) Q. Xiao, J. Sheng, Q. Ding, J. Wu, *Eur. J. Org. Chem.*, 2014, **2014**, 217–221; c) R. Karmakar, P. Mamidipalli, R. M. Salzman, S. Hong, S. Y. Yun, W. Guo, Y. Xia, D. Lee, *Org. Lett.*, 2016, **18**, 3530–3533; d) Y. F. Qiu, X. R. Song, M. Li, X. Y. Zhu, A. Q. Wang, F. Yang, Y. P. Han, H. R. Zhang, D. P. Jin, Y. X. Li, Y. M. Liang, *Org. Lett.*, 2016, **18**, 1514–1517.
- 13 H. Y. Xiang, C. H. Yang, Org. Lett., 2014, 16, 5686–5689.
- 14 a) J. Zheng, Y. Zhang, D. H. Wang, S. L. Cui, Org. Lett., 2016, 18, 1768–1771; b) X. K. Liu, P. Qian, Y. Wang, Y. Pan, Org. Chem. Front., 2017, 4, 2370–2374; c) J. Zheng, Z. Y. Deng, Y. Zhang, S. L. Cui, Adv. Synth. Catal., 2016, 358, 746–751.
- 15 a) J. Dong, X. Lv, Z. Wang, X. Wang, H. Song, Y. Liu, Q. Wang, *Chem. Sci.*, 2019, **10**, 976–982; b) J. Dong, Q. Xia, X. Lv, C. Yan, H. Song, Y. Liu, Q. Wang, *Org. Lett.*, 2018, **20**, 5661–5665; c) J. Dong, X. Wang, Z. Wang, H. Song, Y. Liu, Q. Wang, *Chem. Commun.*, 2019, **55**, 11707–11710; d) G. Li, R. He, Q. Liu, Z. Wang, Y. Liu, Q. Wang, *J. Org. Chem.*, 2019, **84**, 8646–8660.

Organic & Biomolecular Chemistry Accepted Manuscript

View Article Online DOI: 10.1039/D00B00233J

ARTICLE

Graphical Abstract



An efficient strategy for synthesis of SCF₃-substituted tryptanthrin derivatives was developed with AgSCF₃/K₂S₂O₈-promoted radical trifluoromethylthiolation/cyclization cascade reaction as key step.

Organic & Biomolecular Chemistry Accepted Manuscript

Table of contents entry



An efficient strategy for synthesis of SCF_3 -substituted tryptanthrin derivatives was developed with $AgSCF_3/K_2S_2O_8$ -promoted radical trifluoromethylthiolation/cyclization cascade reaction as key step.